Monitoring the Clues in the Diagnosis and Management of PF-ILD
Kristin B. Highland, MD
Pulmonary/Critical Care Medicine
Director, Rheumatic Lung Disease Program
Steven D. Nathan, MD
Professor of Medicine
Virginia Commonwealth University - Inova Fairfax campus
Medical Director, Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA
This activity is provided by Paradigm Medical Communications, LLC.
In partnership with the Pulmonary Fibrosis Foundation.
Disclosure of Commercial Support
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
This activity has been designed to meet the educational needs of pulmonologists, radiologists, and pathologists. It may also be of benefit to primary care physicians, PAs, nurse practitioners, nurses, pharmacists, fellows, residents, and other healthcare professionals who care for patients with chronic progressive fibrosing interstitial lung disease (PF-ILD).
Upon completion of this activity, participants should be able to:
- Compare PF-ILD subtypes and the pathophysiology associated with increased risk of progression
- Evaluate the risk of progression among patients with PF-ILD based on laboratory data
- Assess evidence from recent and ongoing clinical trials for clinical implications in the management of PF-ILD
- Introduction PF-ILD
- Case 1: Patient presents with shortness of breath and skin thickening on hands
- Case 2: 68-year-old man with a dry cough
- Case 3: 56-year-old woman with upper respiratory infection symptoms
- Summary: Diagnosis of PF-ILD
- Summary: Treatment of PF-ILD
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
How to Receive Your CME Credit
To receive a CME certificate of participation, you must:
- Follow instructions to register or log in with your professional information and complete the preactivity assessment
- Attend the live activity
- Complete and submit the online posttest and evaluation
A certificate of participation will be available for download/printing following your successful completion of the posttest and evaluation.
For questions regarding CME credit, contact the Paradigm CME Department at firstname.lastname@example.org or (845) 398-5949.
There is no fee required for participation in this activity.
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Kristin B. Highland, MD
Consulting Fees: Actelion Pharmaceuticals Ltd; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc; United Therapeutics Corporation
Speakers Bureau: Actelion Pharmaceuticals Ltd; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc; United Therapeutics Corporation
Grant/Research Support: Actelion Pharmaceuticals Ltd; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc; United Therapeutics Corporation
Steven D. Nathan, MD
Consulting Fees: Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc; Galapagos NV; Genentech, Inc; United Therapeutics Corporation
Speakers Bureau: Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Independent peer and resident/fellow reviewers have no financial relationships to disclose.
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity has been independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for use have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
© 2020 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.